Diabeloop reported on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. Data was presented at the

While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low. Users share how these clinical results, combined with a growing trust in the algorithm has led to fewer interactions with the device and improved quality of life.

In line with previously presented data, significant improvement in Time in Range is observed here in a much larger population. The cohort gathers 4,162 patients in five countries: Germany, Italy, Spain, The Netherlands, and Switzerland. TIR gain is 17.6% points over a year of real-life use. 

Another significant result is that this improvement in time spent in the target range is combined with a still extremely low occurrence of hypoglycemia: 0.2% < 54 mg/dL, 1.1% < 70 mg/dL. For the patients’ clinical picture and for their overall quality of life, this means less than 20 minutes per day spent in hypoglycemia, whereas the maximum accepted in the international recommendations is 60 minutes. 

“When initiating a treatment with DBLG1, it can be expected that the recommended outcomes (i.e., a TIR>70%, a TBR<4% and a GMI< 7%) will be achieved in about half of patients,” said Pierre-Yves Benhamou, CMO and President of Diabeloop’s scientific committee and US advisory board. “Currently in Europe, the rate of achievement with standard treatment is only 27%.”